285 related articles for article (PubMed ID: 12709793)
1. Parasite-specific trypanothione reductase as a drug target molecule.
Krauth-Siegel RL; Inhoff O
Parasitol Res; 2003 Jun; 90 Suppl 2():S77-85. PubMed ID: 12709793
[TBL] [Abstract][Full Text] [Related]
2. Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development.
Schmidt A; Krauth-Siegel RL
Curr Top Med Chem; 2002 Nov; 2(11):1239-59. PubMed ID: 12171583
[TBL] [Abstract][Full Text] [Related]
3. Thiol redox biology of trypanosomatids and potential targets for chemotherapy.
Leroux AE; Krauth-Siegel RL
Mol Biochem Parasitol; 2016; 206(1-2):67-74. PubMed ID: 26592324
[TBL] [Abstract][Full Text] [Related]
4. Flavoprotein structure and mechanism. 5. Trypanothione reductase and lipoamide dehydrogenase as targets for a structure-based drug design.
Krauth-Siegel RL; Schöneck R
FASEB J; 1995 Sep; 9(12):1138-46. PubMed ID: 7672506
[TBL] [Abstract][Full Text] [Related]
5. The parasite-specific trypanothione metabolism of trypanosoma and leishmania.
Krauth-Siegel RL; Meiering SK; Schmidt H
Biol Chem; 2003 Apr; 384(4):539-49. PubMed ID: 12751784
[TBL] [Abstract][Full Text] [Related]
6. Information-based methods in the development of antiparasitic drugs.
Wolf K; Dormeyer M
Parasitol Res; 2003 Jun; 90 Suppl 2():S91-6. PubMed ID: 12937970
[TBL] [Abstract][Full Text] [Related]
7. Use of an additional hydrophobic binding site, the Z site, in the rational drug design of a new class of stronger trypanothione reductase inhibitor, quaternary alkylammonium phenothiazines.
Khan MO; Austin SE; Chan C; Yin H; Marks D; Vaghjiani SN; Kendrick H; Yardley V; Croft SL; Douglas KT
J Med Chem; 2000 Aug; 43(16):3148-56. PubMed ID: 10956223
[TBL] [Abstract][Full Text] [Related]
8. Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease.
Beltran-Hortelano I; Perez-Silanes S; Galiano S
Curr Med Chem; 2017 May; 24(11):1066-1138. PubMed ID: 28025938
[TBL] [Abstract][Full Text] [Related]
9. Biological Evaluation and X-ray Co-crystal Structures of Cyclohexylpyrrolidine Ligands for Trypanothione Reductase, an Enzyme from the Redox Metabolism of Trypanosoma.
De Gasparo R; Brodbeck-Persch E; Bryson S; Hentzen NB; Kaiser M; Pai EF; Krauth-Siegel RL; Diederich F
ChemMedChem; 2018 May; 13(9):957-967. PubMed ID: 29624890
[TBL] [Abstract][Full Text] [Related]
10. Molecular studies on trypanothione reductase, a target for antiparasitic drugs.
Walsh C; Bradley M; Nadeau K
Trends Biochem Sci; 1991 Aug; 16(8):305-9. PubMed ID: 1957352
[TBL] [Abstract][Full Text] [Related]
11. Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
Chan C; Yin H; Garforth J; McKie JH; Jaouhari R; Speers P; Douglas KT; Rock PJ; Yardley V; Croft SL; Fairlamb AH
J Med Chem; 1998 Jan; 41(2):148-56. PubMed ID: 9457238
[TBL] [Abstract][Full Text] [Related]
12. Redox enzyme engineering: conversion of human glutathione reductase into a trypanothione reductase.
Bradley M; Bücheler US; Walsh CT
Biochemistry; 1991 Jun; 30(25):6124-7. PubMed ID: 2059620
[TBL] [Abstract][Full Text] [Related]
13. Privileged structure-guided synthesis of quinazoline derivatives as inhibitors of trypanothione reductase.
Cavalli A; Lizzi F; Bongarzone S; Brun R; Luise Krauth-Siegel R; Bolognesi ML
Bioorg Med Chem Lett; 2009 Jun; 19(11):3031-5. PubMed ID: 19414258
[TBL] [Abstract][Full Text] [Related]
14. Improved inhibitors of trypanothione reductase by combination of motifs: synthesis, inhibitory potency, binding mode, and antiprotozoal activities.
Eberle C; Lauber BS; Fankhauser D; Kaiser M; Brun R; Krauth-Siegel RL; Diederich F
ChemMedChem; 2011 Feb; 6(2):292-301. PubMed ID: 21275053
[TBL] [Abstract][Full Text] [Related]
15. Molecular insights into trypanothione reductase-inhibitor interaction: A structure-based review.
Tiwari N; Tanwar N; Munde M
Arch Pharm (Weinheim); 2018 Jun; 351(6):e1700373. PubMed ID: 29672908
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of trypanothione reductase by substrate analogues.
Garrard EA; Borman EC; Cook BN; Pike EJ; Alberg DG
Org Lett; 2000 Nov; 2(23):3639-42. PubMed ID: 11073664
[TBL] [Abstract][Full Text] [Related]
17. Targeting Trypanothione Metabolism in Trypanosomatids.
González-Montero MC; Andrés-Rodríguez J; García-Fernández N; Pérez-Pertejo Y; Reguera RM; Balaña-Fouce R; García-Estrada C
Molecules; 2024 May; 29(10):. PubMed ID: 38792079
[TBL] [Abstract][Full Text] [Related]
18.
Matadamas-Martínez F; Hernández-Campos A; Téllez-Valencia A; Vázquez-Raygoza A; Comparán-Alarcón S; Yépez-Mulia L; Castillo R
Molecules; 2019 Sep; 24(18):. PubMed ID: 31487860
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential trypanothione reductase inhibitors among commercially available β-carboline derivatives using chemical space, lead-like and drug-like filters, pharmacophore models and molecular docking.
Rodríguez-Becerra J; Cáceres-Jensen L; Hernández-Ramos J; Barrientos L
Mol Divers; 2017 Aug; 21(3):697-711. PubMed ID: 28656524
[TBL] [Abstract][Full Text] [Related]
20. Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism.
Krauth-Siegel RL; Comini MA
Biochim Biophys Acta; 2008 Nov; 1780(11):1236-48. PubMed ID: 18395526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
